https://www.selleckchem.com/pr....oducts/SB-525334.htm
Treatment discontinuation rates were lower than those in clinical trials. Real-life experience in a community-based hospital confirms the efficacy and safety profile of ruxolitinib in intermediate-risk myelofibrosis. Treatment discontinuation rates were lower than those in clinical trials. Three-dimensional cultures of human pancreatic cancer tissue also known as "organoids" have largely been developed from surgical specimens. Given that most patients present with locally advanced and/or metastatic disease, such organoids are not repr
Like
Comment
Share
